Ambryon Biosciences

MyoAAV-1A Serotype

Lead muscle-tropic AAV capsid from M-CREATE directed evolution with 100-fold greater skeletal and cardiac muscle transduction than AAV9. Cross-species validated in mouse, pig, and non-human primate with substantially reduced liver off-target uptake. Primary delivery vector for Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and cardiomyopathy gene therapy.

TropismSkeletal muscle, cardiac muscle, cross-species validated

Characteristics

100-fold enhanced muscle transduction versus AAV9. M-CREATE (muscle-tropic CREATE) selection in mice. Cross-species efficacy in mouse, pig, and NHP. Reduced liver uptake and immune activation. Peptide insertion conferring muscle-specific receptor binding.

Applications

Duchenne muscular dystrophy gene therapy. Limb-girdle muscular dystrophies. Cardiomyopathies. Translational muscle gene therapy (validated in large animals).

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Tabebordbar et al. (2021). Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell — Tabebordbar 2021 MyoAAV

Identifiers & revision